Evidence map›Paper›PMID 40948827›Full record

ArticleTranslational lung cancer research2025

Enhancing the sensitivity of lung adenocarcinoma to immune therapeutic agents through

Chen Wu, Lingling Ma, Yi Wang, Joanna Bidzińska, Yilang Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chen WuDepartment of Science and Education, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong, China.
Lingling MaDepartment of Science and Education, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong, China.
Yi WangDepartment of Science and Education, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong, China.
Joanna Bidzińska2nd Department of Radiology, Medical University of Gdansk, Gdansk, Poland.
Yilang WangDepartment of Science and Education, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Programmed death-ligand 1 (PD-L1), a classic immune checkpoint, is a key target for immunotherapy. Research has demonstrated that Sprouty-related Methods: In this study, bioinformatics technologies were employed to examine the interaction between Results: Bioinformatics analyses revealed that Conclusions:

Indexed as

immunotherapeutic sensitivityLung adenocarcinoma (LUAD)programmed death-ligand 1 (PD-L1)Sprouty-related EVH1 domain-containing 1 (SPRED1)

Identifiers

PMID40948827
PMCPMC12432670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.